A rumor regarding Ascendis Pharma (ASND) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $256 from $254 at Stifel
- Ascendis Pharma Grants Employee Warrants to Strengthen Market Position
- Positive Outlook for Ascendis Pharma: Buy Rating Despite PDUFA Delay
- Ascendis Pharma Faces FDA Delay for TransCon CNP Approval
- Positive Outlook on Ascendis Pharma Despite PDUFA Date Extension for TransCon CNP